Q2 2024 · 13F-HR
Boxer Capital, LLCholdings as filed
Filed 2024-08-14 · accession 0000895345-24-000355
$1.90B
Reported value
61
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 76155X100 | RVMD | Revolution Medicines Inc | $166.1M | 8.75% | 4,279,464 | Common | SOLE |
| 85205L107 | SWTXUSD | Springworks Therapeutics Inc | $128.9M | 6.79% | 3,421,541 | Common | SOLE |
| 23282W605 | CYTK | Cytokinetics Inc | $113.8M | 5.99% | 2,100,000 | Common | SOLE |
| N5749R100 | 2GH | Merus N V | $112.4M | 5.92% | 1,900,000 | Common | SOLE |
| 90240B106 | TYRA | Tyra Biosciences Inc | $103.1M | 5.43% | 6,448,359 | Common | SOLE |
| 803607100 | SRPT | Sarepta Therapeutics Inc | $102.7M | 5.41% | 650,000 | Common | SOLE |
| 670703107 | NUVL | Nuvalent Inc | $85.0M | 4.48% | 1,120,192 | Common | SOLE |
| 45166A102 | IDYA | Ideaya Biosciences Inc | $77.3M | 4.07% | 2,202,812 | Common | SOLE |
| 07725L102 | ONC | BeiGene Ltd | $71.3M | 3.76% | 500,000 | Common | SOLE |
| 05370A108 | RNAGBP | Avidity Biosciences Inc | $70.6M | 3.72% | 1,727,388 | Common | SOLE |
| 87583X109 | TNGX | Tango Therapeutics Inc | $70.3M | 3.70% | 8,198,642 | Common | SOLE |
| 03753U106 | APLSUSD | Apellis Pharmaceuticals Inc | $66.2M | 3.49% | 1,726,000 | Common | SOLE |
| 46565G104 | 5E7 | iTeos Therapeutics Inc | $43.7M | 2.30% | 2,946,915 | Common | SOLE |
| 04016X101 | ARGX | Argenx SE | $43.0M | 2.26% | 100,000 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics Inc | $39.3M | 2.07% | 1,676,733 | Common | SOLE |
| 65487U108 | NKTX | Nkarta Inc | $33.1M | 1.75% | 5,607,350 | Common | SOLE |
| 032724106 | ANAB | AnaptysBio Inc | $32.6M | 1.72% | 1,300,000 | Common | SOLE |
| 05464T104 | AXSM | Axsome Therapeutics Inc | $32.2M | 1.70% | 400,000 | Common | SOLE |
| 77313F106 | RCKT | Rocket Pharmaceuticals Inc | $31.6M | 1.66% | 1,466,051 | Common | SOLE |
| 31189P102 | FATE | Fate Therapeutics Inc | $26.9M | 1.42% | 8,215,910 | Common | SOLE |
| 52490G102 | LEGN | Legend Biotech Corp | $26.6M | 1.40% | 600,000 | Common | SOLE |
| 88427A107 | — | Third Harmonic Bio Inc | $26.0M | 1.37% | 2,000,000 | Common | SOLE |
| 374163103 | GERN | Geron Corp | $25.4M | 1.34% | 6,000,000 | Common | SOLE |
| 03969F109 | RCUS | Arcus Biosciences Inc | $24.4M | 1.29% | 1,602,200 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc | $23.4M | 1.23% | 600,000 | Common | SOLE |
| 45258J102 | IMVT | Immunovant Inc | $21.8M | 1.15% | 825,000 | Common | SOLE |
| 50127T109 | KURA | Kura Oncology Inc | $20.6M | 1.08% | 1,000,000 | Common | SOLE |
| 483497103 | KALV | Kalvista Pharmaceuticals Inc | $18.7M | 0.99% | 1,590,000 | Common | SOLE |
| 28658R106 | CLYM | Eliem Therapeutics Inc | $18.5M | 0.97% | 2,603,190 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals I | $16.4M | 0.86% | 1,189,943 | Common | SOLE |
| 00773J202 | SYRE | Spyre Therapeutics Inc | $16.4M | 0.86% | 696,480 | Common | SOLE |
| 04335A105 | ARVN | Arvinas Inc | $16.2M | 0.85% | 608,614 | Common | SOLE |
| 86366E106 | GPCR | Structure Therapeutics Inc | $15.7M | 0.83% | 400,000 | Common | SOLE |
| 29337E102 | ELVN | Enliven Therapeutics Inc | $15.7M | 0.83% | 671,358 | Common | SOLE |
| G72800108 | PRTA | Prothena Corp PLC | $14.2M | 0.75% | 690,000 | Common | SOLE |
| 76029N106 | REPL | Replimune Group Inc | $13.8M | 0.73% | 1,536,341 | Common | SOLE |
| 73730P108 | PSTXUSD | Poseida Therapeutics | $13.1M | 0.69% | 4,475,000 | Common | SOLE |
| 15673T100 | IPSC | Century Therapeutics Inc | $12.5M | 0.66% | 4,901,603 | Common | SOLE |
| 68622P109 | ORIC | Oric Pharmaceuticals Inc | $12.2M | 0.65% | 1,732,571 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics Inc | $11.9M | 0.62% | 1,819,132 | Common | SOLE |
| 230031106 | CGEM | Cullinan Therapeutics Inc | $11.5M | 0.60% | 657,895 | Common | SOLE |
| 74065P101 | PRLD | Prelude Therapeutics Inc | $9.8M | 0.52% | 2,568,287 | Common | SOLE |
| 019770106 | ALLO | Allogene Therapeutics Inc | $9.0M | 0.47% | 3,850,000 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology Inc | $8.4M | 0.44% | 1,545,000 | Common | SOLE |
| 471871202 | JSPR | Jasper Therapeutics Inc | $7.9M | 0.42% | 350,000 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals Inc | $7.0M | 0.37% | 650,000 | Common | SOLE |
| 29286M105 | — | Engene Holdings Inc | $6.9M | 0.36% | 727,900 | Common | SOLE |
| 462260100 | IOVA | Iovance Biotherapeutics Inc | $6.0M | 0.32% | 750,000 | Common | SOLE |
| 03237H101 | AMLX | Amylyx Pharmaceuticals Inc | $2.9M | 0.15% | 1,500,000 | Common | SOLE |
| 10170A100 | BOLD | Boundless Bio Inc | $2.8M | 0.14% | 711,329 | Common | SOLE |
| 09203E105 | BDTX | Black Diamond Therapeutics I | $2.4M | 0.12% | 506,000 | Common | SOLE |
| 00091E109 | ABSI | ABSCI Corporation | $2.2M | 0.11% | 700,000 | Common | SOLE |
| 68572M106 | OBIO | Orchestra Biomed Hldgs Inc | $1.9M | 0.10% | 238,193 | Common | SOLE |
| 98943L107 | ZNTL | Zentalis Pharmaceuticals Inc | $1.8M | 0.10% | 450,000 | Common | SOLE |
| 74365U107 | TARA | Protara Therapeutics Inc | $1.7M | 0.09% | 811,627 | Common | SOLE |
| 046513107 | ATRAGBX | Atara Biotherapeutics Inc | $1.4M | 0.07% | 166,000 | Common | SOLE |
| 09077B104 | BCABGBP | BioAtla Inc | $940,295 | 0.05% | 686,347 | Common | SOLE |
| 59935V107 | MIST | Milestone Pharmaceuticals In | $407,889 | 0.02% | 309,007 | Common | SOLE |
| 23306J101 | — | DBV Technologies S A | $200,250 | 0.01% | 250,000 | Common | SOLE |
| 67080N119 | NUVB/WS | Nuvation Bio Inc | $42,667 | 0.00% | 266,666 | Common | SOLE |
| 86889P117 | SRZNW | Surrozen Inc | $1,107 | 0.00% | 66,666 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.